Every 10-Q that Silo Pharma, Inc. (SILO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SILO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SILO filings page.
Silo Pharma, Inc. reported that total assets were $5.95 million at June 30, 2026, down from $7.61 million at year-end 2025, driven mainly by the use of cash for operations. Cash and cash equivalents were $3.28 million, with short-term investments of $1.95 million and crypto assets at fair value of $205,414.
For the six months ended June 30, 2026, the company generated $18,026 in license fee revenue and recorded a net loss of $2,479,946, compared with a net loss of $2,235,730 a year earlier. Research and development expenses were $1,311,683, reflecting continued investment in its psychedelic-based drug candidates and new AI-agent platform.
The company reported working capital of $4,647,793 and stated that this, together with a July 2026 private placement, mitigates prior substantial doubt about its ability to continue as a going concern. Shares outstanding were 1,128,610 at June 30, 2026 and 1,588,250 as of August 13, 2026, following equity issuances and a 1‑for‑15 reverse stock split effective June 2026.
Silo Pharma reported a Q1 2026 net loss of $1,647,117, wider than a year earlier, as it increased spending on research and development and recorded losses on its cryptocurrency holdings. Revenue remained minimal at $18,026 from license fees, underscoring its early-stage status.
Cash and cash equivalents were $3,902,514 with short-term investments of $2,129,659, supporting working capital of $6,098,849 as of March 31, 2026. Management states this liquidity is sufficient to meet obligations for at least twelve months, easing prior going-concern concerns.
The company advanced its biopharmaceutical pipeline while diversifying, forming AI-focused subsidiary Qwikagentsai and purchasing AI software and domains for $714,000 in stock, all expensed as R&D. It also recorded an impairment of $29,911 on staked crypto assets and unrealized crypto losses, reflecting volatility in its digital asset treasury strategy.
Silo Pharma, Inc. (SILO) filed its Q3 2025 10‑Q, reporting a net loss of $1,110,438 for the quarter and $3,346,168 for the nine months ended September 30, 2025. License fee revenue was $18,025 in the quarter and $54,076 year‑to‑date, with cost of revenues of $20,687 in the quarter.
Operating expenses were led by R&D at $543,615 in the quarter ($1,854,824 YTD), plus compensation and professional fees. As of September 30, 2025, cash and cash equivalents were $3,917,627, short‑term investments $1,948,579, total assets $6,384,681, and working capital $5,456,030. The company states it has sufficient cash and liquid short‑term investments to meet obligations for a minimum of twelve months from the date of the filing.
During 2025, Silo completed a May public offering with net proceeds of $1,593,897 and received warrant exercise proceeds of $500,000 on June 6 and $634,922 during August–September. It also issued 750,000 shares valued at $518,225 for software assets, recorded as R&D. Crypto assets totaled $72,283 at fair value as of September 30, 2025. Shares outstanding were 13,318,273 as of November 13, 2025.
Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency treasury company advancing therapies for PTSD, fibromyalgia, Alzheimer’s and multiple sclerosis. The company reported cash and cash equivalents of $4.33 million and short-term investments of $1.93 million, giving total assets of $6.65 million and working capital of $5.32 million. Management states available cash and liquid investments are sufficient to meet obligations for at least twelve months.
Operating results show a six-month net loss of $2.24 million versus $1.73 million a year earlier, driven by higher research and development expense of $1.31 million (six months) and total operating expenses of $2.38 million. License fee revenue remains nominal ($36,051 six months) with one licensee accounting for 100% of that revenue. Financing activity increased shares outstanding from 4.48 million to 8.65 million and generated net proceeds of $1.59 million from a May 2025 offering. Outstanding warrants totaled 8,295,072, and intangible assets include a Columbia license revised to $235,000.